Global Bleeding Disorders Treatment Market to Reach US$ 23.9 Billion by 2032, Fueled by Significant Advancements in Medical Technology

September 07, 2023 | Healthcare

According to the latest report by IMARC Group, titled “­­Bleeding Disorders Treatment Market Report by Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, and Others), Drug Class (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores), End User (Hospitals, Clinics, Academic and Research Institutes), and Region 2024-2032,” the global bleeding disorders treatment market size reached US$ 15.0 Billion in 2023. Bleeding disorders treatment encompasses a range of therapeutic interventions aimed at managing conditions characterized by abnormal bleeding due to disruptions in the blood clotting process. These disorders, such as hemophilia, von Willebrand disease, and rare clotting factor deficiencies, can lead to excessive bleeding even from minor injuries or spontaneously. The treatment landscape includes the administration of clotting factor concentrates, both recombinant and derived from human or animal sources, to replace the deficient factors and restore normal clotting function. Besides this, pharmaceutical advancements have led to the development of innovative therapies, including non-factor replacement treatments and gene therapies, which provide longer-term relief for individuals with bleeding disorders.

Global Bleeding Disorders Treatment Market Trends:

The global bleeding disorders treatment market is witnessing robust growth, driven by the increasing prevalence of bleeding disorders worldwide. Besides this, the advent of better diagnostic technologies and increased awareness among healthcare professionals and the general population has spurred early detection and intervention, leading to a larger patient pool seeking treatment options, thus strengthening the market growth. Moreover, the rise in government initiatives and healthcare expenditure in various regions has facilitated improved access to bleeding disorders treatment, creating a favorable outlook for the market. Additionally, significant advancements in medical technology paving the way for more efficient and targeted therapies are presenting lucrative opportunities for market expansion. In line with this, the development of extended half-life clotting factors has reduced the frequency of treatment administrations, enhancing patient convenience and compliance, thereby contributing to the market’s growth. Furthermore, ongoing research and development (R&D) efforts have led to the emergence of gene therapies that aim to address the root causes of bleeding disorders by introducing functional genes and offering long-term solutions for patients with chronic bleeding disorders. This represents another key growth-inducing factor. Apart from this, increased collaborations between pharmaceutical companies and research institutions, driving the discovery of novel treatment modalities and facilitating innovation, is propelling the market forward. Looking forward, the market value is projected to reach US$ 23.9 Billion by 2032, expanding at a CAGR of 5.12% during 2024-2032.

Market Summary:

  • On the basis of the type, the market has been divided into hemophilia A, hemophilia B, Von Willebrand disease, and others.
  • Based on the drug class, the market is classified into plasma-derived coagulation factor concentrates (factor VIII, factor IX, factor for Von Willebrand disease, and activated prothrombin complex concentrate), recombinant coagulation factor concentrates (factor VIII, factor for Von Willebrand disease, and factor IX), desmopressin, antifibrinolytics, fibrin sealants, and others.
  • On the basis of the distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, and online stores.
  • Based on the end user, the market is categorized into hospitals, clinics, and academic and research institutes.
  • On a regional basis, the market has been segmented into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has also been examined, with some of the key players being AbbVie Inc, Alnylam Pharmaceuticals Inc., Bayer AG, CSL Behring (CSL Limited), Grifols S.A., Johnson & Johnson, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Wellona Pharma.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Type, Drug Class, Distribution Channel, End User, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AbbVie Inc, Alnylam Pharmaceuticals Inc., Bayer AG, CSL Behring (CSL Limited), Grifols S.A., Johnson & Johnson, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Wellona Pharma.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Bleeding Disorders Treatment Market to Reach US$ 23.9 Billion by 2032, Fueled by Significant Advancements in Medical Technology
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More